GlassScriptPhysician profile
Alexander Gross
NPI 1306826490
$9,387.63
in general payments reported to CMS, 2019-2025
31 companies · $2,184 in 2025
The $2,184 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $246 · 2021: $947 · 2022: $1,221 · 2023: $1,872 · 2024: $2,084 · 2025: $2,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,074 · Education: $66.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,073.64 |
| Education | $66.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,657.66 | 2019-2025 | |
| Genzyme Corporation | $808.15 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $737.43 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $681.85 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Leo Pharma INC. | $674.13 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $413.97 | 2019-2025 | |
| Pfizer INC. | $386.95 | 2019-2025 | |
| Lilly USA, LLC | $293.68 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $285.78 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $257.83 | 2019-2025 | Winlevi |
| Ucb, INC. | $232.46 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $220.61 | 2019-2025 | Aklief, Twyneo, Oracea |
| Amgen INC. | $188.42 | 2021-2025 | Otezla, Otezla |
| Allergan, INC. | $188.22 | 2020-2022 | |
| Revance Therapeutics, INC. | $183.87 | 2024 | Daxxify |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $183.22 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $155.08 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.39 | 2023-2025 | Spevigo |
| Almirall LLC | $116.23 | 2021-2025 | Klisyri, Seysara |
| Merz North America, INC. | $107.73 | 2021 | |
| Biofrontera INC. | $75.56 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $74.16 | 2021-2025 | Opzelura |
| Epi Health, LLC | $67.16 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $49.23 | 2023 | |
| Journey Medical Corporation | $42.01 | 2021 | |
| Verrica Pharmaceuticals INC. | $37.62 | 2024-2025 | Ycanth |
| Dermira, INC. | $36.18 | 2019 | |
| Botanix Sb INC | $34.36 | 2025 | Sofdra |
| Springworks Therapeutics, INC. | $31.81 | 2025 | Gomekli |
| Organogenesis INC. | $25.02 | 2023 | Puraply |
| Mylan Pharmaceuticals INC. | $23.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.